Adc Therapeutics SA Forecast, price target & analysts
Adc Therapeutics SA Target price 2025 - Analyst rating & recommendation
Adc Therapeutics SA Classifications & Recommendation:
Adc Therapeutics SA Price Target
| Target Price | $9.18 |
| Price | $2.71 |
| Potential |
238.75%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Adc Therapeutics SA 2026 .
The average Adc Therapeutics SA target price is $9.18.
This is
238.75%
register free of charge
$10.50
287.45%
register free of charge
$5.05
86.35%
register free of charge
|
|
| A rating was issued by 12 analysts: 11 Analysts recommend Adc Therapeutics SA to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adc Therapeutics SA stock has an average upside potential 2026 of
238.75%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 70.84 | 78.38 |
| 1.84% | 10.65% | |
| EBITDA Margin | -179.81% | -216.02% |
| 23.13% | 20.14% | |
| Net Margin | -222.83% | -172.69% |
| 35.43% | 22.50% |
8 Analysts have issued a sales forecast Adc Therapeutics SA 2025 . The average Adc Therapeutics SA sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Adc Therapeutics SA EBITDA forecast 2025. The average Adc Therapeutics SA EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Adc Therapeutics SA Analysts have issued a net profit forecast 2025. The average Adc Therapeutics SA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.62 | -1.36 |
| 44.90% | 16.05% | |
| P/E | negative | |
| EV/Sales | 6.57 |
8 Analysts have issued a Adc Therapeutics SA forecast for earnings per share. The average Adc Therapeutics SA EPS is
This results in the following potential growth metrics and future valuations:
Adc Therapeutics SA...
Current Adc Therapeutics SA Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Jun 20 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jun 13 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 20 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jun 13 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Feb 24 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
